ARTICLE | Clinical News

Solorel macimorelin: Phase IIa started

March 12, 2012 7:00 AM UTC

Aeterna Zentaris began a double-blind, placebo-controlled Phase IIa trial to evaluate AEZS-130 in 18-26 patients with cancer cachexia. The trial is being conducted under a cooperative research and development agreement (CRADA) with the Michael E. DeBakey Veterans Affairs Medical Center, which is funding the study.

The compound also completed Phase III testing to diagnose adult growth hormone deficiency (AGHD), with an NDA submission expected this year. The compound has Orphan Drug designation from FDA for the indication (see BioCentury, Sept. 5, 2011). ...